GET DAILY SIGNALSBurning Rock Biotech (BNR): Can It Reach the $16 Target for a +19% Move?
Key Takeaways
- The central price target used here is $16, roughly 19% above the latest verified price near $13.42.
- This target is not an analyst consensus; it is drawn from public technical discussion, specifically a retest of the stock's mid-October 2026 swing high near $16.
- Burning Rock has essentially one active brokerage rating (a Hold), and no reliable, current aggregate analyst price target exists for the shares.
- The strongest supporting factors are improving sales efficiency, a revenue mix shifting toward in-hospital and pharma R&D services, and strong gross margins.
- The biggest risks are persistent losses and negative free cash flow, repeated reverse stock splits, thin liquidity, and China healthcare-policy uncertainty.
- For more detail, explore the ticker's Major News, Today's Price Move, Forecast, and Earnings pages.
- Readers can also explore Trending AI Robots for automated, AI-driven trading ideas across the market.
How the $16 Target Came Into View
Burning Rock Biotech Limited (BNR) lacks a broad analyst consensus. Available information points to just one active rating, a Hold from Jefferies in May 2026, with no clean or current aggregate price target attached. Some widely seen figures like a "$530" target appear to stem from data quirks linked to past share consolidations rather than active estimates, so they do not support a credible average.
Without a reliable consensus figure, the $16 level serves as a practical reference based on visible market structure. It aligns with the stock's recent swing high near $16 from mid-October 2026. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry. This makes it a technical benchmark under discussion rather than an official forecast.
Current Position and the Path to $16
At a latest verified price near $13.42, a move to $16 would mean an advance of roughly 19%. That is a notable shift for a lower-priced name with limited liquidity. The 52-week range of about $6.79 to $41.72 highlights the stock's sharp swings, influenced in part by reverse stock splits including a 1-for-10 in 2024 and 1-for-10 plus 1-for-20 actions in 2026.
Reaching $16 would likely hinge on revenue stabilization, clearer progress in the in-hospital and pharma R&D service areas, and renewed interest from investors. With a limited float and average daily volume in the tens of thousands of shares, even modest buying can drive sizable percentage changes.
Elements That Could Support an Upside Move
Several factors stand out as potential positives. The company has shown strong gross margins and better operating efficiency, with sales and marketing costs declining as a percentage of revenue. Revenue has tilted more toward in-hospital testing and pharmaceutical R&D services, which management views as steadier and higher-margin areas. A solid cash position offers some buffer while the business moves toward profitability.
From a technical standpoint, reclaiming the mid-October high near $16 could serve as its own bullish indicator. The stock's past pattern of quick, high-volume rallies suggests sentiment can turn rapidly in small-cap diagnostics names.
Obstacles That Could Stand in the Way
Challenges remain straightforward. Burning Rock continues to report losses with negative EPS and negative operating and free cash flow, leaving it reliant on cash reserves and potential capital raises. Revenue has faced pressure, and the company has used repeated reverse stock splits to maintain Nasdaq compliance, which often signals ongoing strain.
Liquidity stands out as a real concern. A thin float and low daily volume make the shares susceptible to large moves in either direction, and major holders can exert significant influence. Changes in China's healthcare and diagnostics reimbursement or regulatory environment add further uncertainty around demand and pricing.
Important Technical Levels
Key reference points include the recent swing high near $16, which now serves as immediate overhead resistance matching the target level. On the downside, support has appeared in the roughly $10 to $11 area during late October and early November 2026. The broader 52-week range should be viewed with caution due to the effects of multiple share consolidations rather than as a straightforward trend channel.
Time Horizon and Items Worth Monitoring
Technical targets like retesting a prior swing high do not come with a fixed timeframe the way many 12-month analyst targets do. I’m watching this closely for the next quarterly results, any updates on cash use and the route to profitability, shifts in analyst ratings, and developments around China diagnostics policy. With limited coverage, even one new rating or target adjustment could have an outsized effect on the shares.
Final Assessment
Can BNR reach $16? The question makes sense because the level ties directly to an observable point—the mid-October swing high—and would require a meaningful yet not extreme advance of about 19%. Supporting elements include better operating efficiency, a shift toward higher-margin revenue, and the stock’s history of sharp rallies. Counterbalancing factors include ongoing losses, negative cash flow, multiple reverse splits, thin liquidity, and policy risks in China. Because this remains a technical reference rather than a consensus estimate, it serves best as a level to observe while tracking earnings, cash-flow trends, and any new analyst input.
Using Tickeron’s AI Daily Buy/Sell Signals
In my own review process, Tickeron's AI Daily Buy/Sell Signals provide a helpful layer by applying artificial intelligence to scan thousands of stocks and ETFs for Buy, Sell, or Hold indications based on market shifts and technical patterns. For a name like Burning Rock with its volatility and lower trading volume, these signals can offer a structured way to track trends and complement manual checks. I find them useful as one part of a broader research approach.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
BNR in downward trend: price dove below 50-day moving average on October 23, 2026
BNR moved below its 50-day moving average on October 23, 2026 date and that indicates a change from an upward trend to a downward trend. In 27 of 29 similar past instances, the stock price decreased further within the following month. The odds of a continued downward trend are 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
The 10-day moving average for BNR crossed bearishly below the 50-day moving average on October 27, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 11 of 12 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BNR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for BNR entered a downward trend on November 06, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on November 05, 2026. You may want to consider a long position or call options on BNR as a result. In 66 of 84 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 79%.
The Moving Average Convergence Divergence (MACD) for BNR just turned positive on November 06, 2026. Looking at past instances where BNR's MACD turned positive, the stock continued to rise in 35 of 47 cases over the following month. The odds of a continued upward trend are 74%.
Following a +4.60% 3-day Advance, the price is estimated to grow further. Considering data from situations where BNR advanced for three days, in 192 of 234 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
BNR may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Seasonality Score of 24 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 46 (best 1 - 100 worst), indicating fairly steady price growth. BNR’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 47 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.258) is normal, around the industry mean (67.298). P/E Ratio (-1.157) is within average values for comparable stocks, (4.239). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.473). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (1.741) is also within normal values, averaging (9.775).
The Tickeron PE Growth Rating for this company is 82 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 95 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BNR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 86, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a company, which engages in the investment of medical fields and specializes in next-generation sequencing diagnostics solutions for precision medicine in oncology
Industry MedicalSpecialties
Advertisement